Summit Therapeutics Inc. Net Income
Summit Therapeutics Inc. (SMMT) reported Net Income of -$215.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-07-23
- Summit Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$215.70M.
- Summit Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$189.42M.
- Summit Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$219.17M.
- Summit Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$231.79M.
- Summit Therapeutics Inc. net income (loss) attributable to parent for fiscal 2020 was -$52.70M.
- Summit Therapeutics Inc. net income (loss) attributable to parent for fiscal 2019 was $10.87M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 11 month | Net Income (Loss) Attributable to Parent 11 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$215.70M 10-Q · filed 2026-07-23 | -$405.12M 10-Q · filed 2026-07-23 | -$624.30M derived: sum of 3 quarters · filed 2026-07-23 | -$856.09M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2026-03-31 | -$189.42M 10-Q · filed 2026-07-23 | -$408.60M derived: sum of 2 quarters · filed 2026-07-23 | -$640.39M derived: sum of 3 quarters · filed 2026-07-23 | -$1.21B derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-12-31 | -$219.17M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | -$450.96M derived: sum of 2 quarters · filed 2026-04-17 | -$1.02B derived: sum of 3 quarters · filed 2026-07-23 | -$1.08B DEF 14A · filed 2026-04-17 | ||||||
| 2025-09-30 | -$231.79M 10-Q · filed 2025-10-20 | -$797.50M derived: sum of 2 quarters · filed 2026-07-23 | -$860.41M 10-Q · filed 2025-10-20 | -$921.62M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-06-30 | -$565.71M 10-Q · filed 2026-07-23 | -$628.62M 10-Q · filed 2026-07-23 | -$689.82M derived: sum of 3 quarters · filed 2026-07-23 | -$746.08M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2025-03-31 | -$62.91M 10-Q · filed 2026-07-23 | -$124.12M derived: sum of 2 quarters · filed 2026-07-23 | -$180.37M derived: sum of 3 quarters · filed 2026-07-23 | -$240.75M derived: sum of 4 quarters · filed 2026-07-23 | ||||||
| 2024-12-31 | -$61.20M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | -$117.46M derived: sum of 2 quarters · filed 2026-04-17 | -$177.84M derived: sum of 3 quarters · filed 2026-04-17 | -$221.31M DEF 14A · filed 2026-04-17 | ||||||
| 2024-09-30 | -$56.25M 10-Q · filed 2025-10-20 | -$116.64M derived: sum of 2 quarters · filed 2025-10-20 | -$160.11M 10-Q · filed 2025-10-20 | -$196.68M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2024-06-30 | -$60.38M 10-Q · filed 2025-10-20 | -$103.86M 10-Q · filed 2025-08-11 | -$140.43M derived: sum of 3 quarters · filed 2026-04-17 | -$161.69M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2024-03-31 | -$43.47M 10-Q · filed 2025-10-20 | -$80.04M derived: sum of 2 quarters · filed 2026-04-17 | -$101.31M derived: sum of 3 quarters · filed 2026-04-17 | -$116.03M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2023-12-31 | -$36.57M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | -$57.84M derived: sum of 2 quarters · filed 2026-04-17 | -$72.55M derived: sum of 3 quarters · filed 2026-04-17 | -$614.93M DEF 14A · filed 2026-04-17 | ||||||
| 2023-09-30 | -$21.27M 10-Q · filed 2024-10-30 | -$35.98M derived: sum of 2 quarters · filed 2024-10-30 | -$578.36M 10-Q · filed 2024-10-30 | -$597.59M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2023-06-30 | -$14.72M 10-Q · filed 2024-08-06 | -$557.09M 10-Q · filed 2024-08-06 | -$576.32M derived: sum of 3 quarters · filed 2026-04-17 | -$597.71M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2023-03-31 | -$542.38M 10-Q · filed 2024-05-01 | -$561.61M derived: sum of 2 quarters · filed 2026-04-17 | -$582.99M derived: sum of 3 quarters · filed 2026-04-17 | -$599.76M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2022-12-31 | -$19.23M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | -$40.61M derived: sum of 2 quarters · filed 2026-04-17 | -$57.38M derived: sum of 3 quarters · filed 2026-04-17 | -$78.78M DEF 14A · filed 2026-04-17 | ||||||
| 2022-09-30 | -$21.39M 10-Q · filed 2023-11-07 | -$38.16M derived: sum of 2 quarters · filed 2023-11-07 | -$59.55M 10-Q · filed 2023-11-07 | -$86.65M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2022-06-30 | -$16.77M 10-Q · filed 2023-08-09 | -$38.17M 10-Q · filed 2023-08-09 | -$65.27M derived: sum of 3 quarters · filed 2026-04-17 | -$84.87M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2022-03-31 | -$21.40M 10-Q · filed 2023-05-11 | -$48.50M derived: sum of 2 quarters · filed 2026-04-17 | -$68.09M derived: sum of 3 quarters · filed 2026-04-17 | -$92.51M derived: sum of 4 quarters · filed 2026-04-17 | ||||||
| 2021-12-31 | -$27.10M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | -$46.70M derived: sum of 2 quarters · filed 2026-04-17 | -$71.11M derived: sum of 3 quarters · filed 2026-04-17 | -$88.60M DEF 14A · filed 2026-04-17 | ||||||
| 2021-09-30 | -$19.60M 10-Q · filed 2022-11-09 | -$44.02M derived: sum of 2 quarters · filed 2022-11-09 | -$61.50M 10-Q · filed 2022-11-09 | -$75.04M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-06-30 | -$24.42M 10-Q · filed 2022-08-11 | -$41.90M 10-Q · filed 2022-08-11 | -$55.45M derived: sum of 3 quarters · filed 2022-12-21 | -$73.19M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-03-31 | -$17.49M 10-Q · filed 2022-05-11 | -$31.03M derived: sum of 2 quarters · filed 2022-12-21 | -$48.77M derived: sum of 3 quarters · filed 2022-12-21 | -$64.05M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2020-12-31 | -$13.54M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | -$31.28M derived: sum of 2 quarters · filed 2022-12-21 | -$46.56M derived: sum of 3 quarters · filed 2022-12-21 | -$52.70M 10-K/A · filed 2022-12-21 | ||||||
| 2020-09-30 | -$17.74M 10-Q · filed 2021-11-15 | -$17.70M 10-Q · filed 2020-11-16 | -$33.02M derived: sum of 2 quarters · filed 2021-11-15 | -$39.16M 10-Q · filed 2021-11-15 | -$39.26M 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | -$15.28M 10-Q · filed 2021-08-12 | -$15.23M 8-K · filed 2020-09-29 | -$21.41M 10-Q · filed 2021-08-12 | -$21.55M 8-K · filed 2020-09-29 | ||||||
| 2020-03-31 | -$6.13M 10-Q · filed 2021-05-17 | |||||||||
| 2019-12-31 | -$29.13M 10-K · filed 2021-03-31 | -$28.98M 8-K · filed 2020-09-29 | ||||||||
| 2019-09-30 | -$6.38M 10-Q · filed 2020-11-16 | -$13.06M derived: sum of 2 quarters · filed 2020-11-16 | -$20.05M 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | -$6.68M 8-K · filed 2020-09-29 | -$13.67M 8-K · filed 2020-09-29 | ||||||||
| 2019-01-31 | $10.87M 10-K · filed 2021-03-31 | $9.90M 8-K · filed 2020-09-29 | ||||||||
| 2018-01-31 | -$26.35M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |